✦ LIBER ✦

Clinical uses of prosthetic devices in brachiotherapy for oral cavity tumors

✍ Scribed by M. Sela; Z. Weshler; E. Loewental; S. Taicher

Publisher: John Wiley and Sons
Year: 1985
Tongue: English
Weight: 315 KB
Volume: 30
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.2930300109

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Experience in using flexible echoprobes

Experience in using flexible echoprobes in ultrasonic diagnosis of tumors of the oral cavity

✍ A. A. Fazylov; A. M. Dusmuratov 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 352 KB

The importance of In situ light dosimetr

The importance of In situ light dosimetry for photodynamic therapy of oral cavity tumors

✍ I. Bing Tan; Hugo Oppelaar; Marjan C. Ruevekamp; Ruth B. Veenhuizen; Adrian Timm 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

Background. Photodynamic therapy (PDT) is being evaluated for treatment of localized head and neck cancer. ''Light dose'' is usually prescribed as incident fluence, which takes no account of reflected and scattered light. This study investigates variations in total tissue fluence for a given inciden

Predictive value of tumor thickness for

Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity : A meta-analysis of reported studies

✍ Shao Hui Huang; David Hwang; Gina Lockwood; David P. Goldstein; Brian O'Sullivan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB 👁 1 views

The Disease Activity Score is not suitab

The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti–tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes

✍ Frederick Wolfe; Kaleb Michaud; Theodore Pincus; Daniel Furst; Edward Keystone 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

## Abstract ## Objective The Disease Activity Score (DAS) is widely used in clinical trials. A DAS of 5.1 defines the level of severe rheumatoid arthritis (RA) and is the criterion for the initiation of anti–tumor necrosis factor therapy in the UK and The Netherlands. In North America, similar rul